Your browser doesn't support javascript.
loading
Volumetric analysis: Rethinking brain metastases response assessment.
Ocaña-Tienda, Beatriz; Pérez-Beteta, Julián; Romero-Rosales, José Antonio; Asenjo, Beatriz; Ortiz de Mendivil, Ana; Pérez Romasanta, Luis Alberto; Albillo Labarra, Jose David; Nagib, Fátima; Vidal Denis, María; Luque, Belén; Arana, Estanislao; Pérez-García, Víctor M.
Afiliação
  • Ocaña-Tienda B; Mathematical Oncology Laboratory, University of Castilla-La Mancha, Ciudad Real, Spain.
  • Pérez-Beteta J; Mathematical Oncology Laboratory, University of Castilla-La Mancha, Ciudad Real, Spain.
  • Romero-Rosales JA; Mathematical Oncology Laboratory, University of Castilla-La Mancha, Ciudad Real, Spain.
  • Asenjo B; Department of Radiology, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
  • Ortiz de Mendivil A; Department of Radiology, Sanchinarro University Hospital, HM Hospitales, Madrid, Spain.
  • Pérez Romasanta LA; Radiation Oncology Service, Salamanca University Hospital, Salamanca, Spain.
  • Albillo Labarra JD; Radiology Unit, MD Anderson Cancer Center, Madrid, Spain.
  • Nagib F; Department of Radiology, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
  • Vidal Denis M; Department of Radiology, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
  • Luque B; Mathematical Oncology Laboratory, University of Castilla-La Mancha, Ciudad Real, Spain.
  • Arana E; Department of Radiology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
  • Pérez-García VM; Mathematical Oncology Laboratory, University of Castilla-La Mancha, Ciudad Real, Spain.
Neurooncol Adv ; 6(1): vdad161, 2024.
Article em En | MEDLINE | ID: mdl-38187872
ABSTRACT

Background:

The Response Assessment in Neuro-Oncology for Brain Metastases (RANO-BM) criteria are the gold standard for assessing brain metastases (BMs) treatment response. However, they are limited by their reliance on 1D, despite the routine use of high-resolution T1-weighted MRI scans for BMs, which allows for 3D measurements. Our study aimed to investigate whether volumetric measurements could improve the response assessment in patients with BMs.

Methods:

We retrospectively evaluated a dataset comprising 783 BMs and analyzed the response of 185 of them from 132 patients who underwent stereotactic radiotherapy between 2007 and 2021 at 5 hospitals. We used T1-weighted MRIs to compute the volume of the lesions. For the volumetric criteria, progressive disease was defined as at least a 30% increase in volume, and partial response was characterized by a 20% volume reduction.

Results:

Our study showed that the proposed volumetric criteria outperformed the RANO-BM criteria in several aspects (1) Evaluating every lesion, while RANO-BM failed to evaluate 9.2% of them. (2) Classifying response effectively in 140 lesions, compared to only 72 lesions classified by RANO-BM. (3) Identifying BM recurrences a median of 3.3 months earlier than RANO-BM criteria.

Conclusions:

Our study demonstrates the superiority of volumetric criteria in improving the response assessment of BMs compared to the RANO-BM criteria. Our proposed criteria allow for evaluation of every lesion, regardless of its size or shape, better classification, and enable earlier identification of progressive disease. Volumetric criteria provide a standardized, reliable, and objective tool for assessing treatment response.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2024 Tipo de documento: Article